Ajo LP maintained its stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,820 shares of the medical research company’s stock at the close of the second quarter. Ajo LP’s holdings in Edwards Lifesciences Corporation were worth $333,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in EW. BlackRock Inc. raised its position in shares of Edwards Lifesciences Corporation by 2,184.9% during the first quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock valued at $1,317,326,000 after buying an additional 13,390,818 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Edwards Lifesciences Corporation by 161.7% during the second quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock valued at $627,207,000 after buying an additional 3,277,726 shares during the last quarter. Egerton Capital UK LLP acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter valued at about $217,805,000. Alliancebernstein L.P. raised its position in shares of Edwards Lifesciences Corporation by 29.8% during the first quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock valued at $598,890,000 after buying an additional 1,459,921 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd acquired a new position in shares of Edwards Lifesciences Corporation during the first quarter valued at about $126,959,000. 82.08% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have recently commented on EW. BidaskClub lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Canaccord Genuity reaffirmed a “buy” rating and set a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Wednesday, June 28th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $129.00 price objective for the company in a research report on Thursday, June 1st. Cowen and Company reaffirmed an “outperform” rating and set a $135.00 price objective (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Finally, Jefferies Group LLC set a $115.00 price objective on shares of Edwards Lifesciences Corporation and gave the company a “buy” rating in a research report on Saturday, May 27th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $120.75.

In other Edwards Lifesciences Corporation news, VP Catherine M. Szyman sold 4,681 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Larry L. Wood sold 18,960 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $112.58, for a total transaction of $2,134,516.80. The disclosure for this sale can be found here. Insiders have sold a total of 182,501 shares of company stock worth $20,847,236 over the last three months. Insiders own 2.13% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/22/edwards-lifesciences-corporation-ew-holdings-maintained-by-ajo-lp.html.

Edwards Lifesciences Corporation (NYSE EW) opened at 110.33 on Friday. The company has a 50-day moving average of $113.80 and a 200 day moving average of $109.37. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75. The firm has a market capitalization of $23.30 billion, a price-to-earnings ratio of 33.46 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.20. The company had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.76 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.